SiBone (SIBN)
(Delayed Data from NSDQ)
$13.49 USD
-0.31 (-2.25%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $13.48 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.49 USD
-0.31 (-2.25%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $13.48 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Zacks News
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Breast Health and GYN Surgical businesses are likely to contribute to Hologic's (HOLX) Q1 2024 revenues.
What's in Store for Boston Scientific (BSX) in Q4 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) fourth-quarter 2023 results are likely to reflect the strength of the Clear Aligner and Systems & Services businesses.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.
Si-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Si-Bone (SIBN) Upgraded to Buy: Here's Why
by Zacks Equity Research
Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Walgreens (WBA) New Study Shows Medical Adherence Importance
by Zacks Equity Research
Walgreens' (WBA) latest research findings highlight the importance of patients adhering to their therapy.
Hologic (HOLX) Gains From New Launches as Macro Concerns Rise
by Zacks Equity Research
Hologic (HOLX) has been making impressive progress in its Breast Health arm, leveraging its strategic expansion efforts to diversify business across the patient continuum of care.
Abbott (ABT) Broadens Electrophysiology Footprint With TactiFlex
by Zacks Equity Research
The successful deployment of Abbott's (ABT) TactiFlex Ablation Catheter, Sensor Enabled in Canada broadens the company's global footprint in the electrophysiology space.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.
Abbott (ABT) Unveils Connected Diabetes App With New Pact
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre portfolio is the world's top sensor-based CGM system, changing the lives of over 5 million people.
Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities
by Zacks Equity Research
Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.
Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.
Phibro (PAHC) Sales Impacted by Macro Concerns, FX Headwind
by Zacks Equity Research
The COVID-19 pandemic has adversely affected the international economic conditions and financial markets, leading to an economic downturn in many countries, in which Phibro (PAHC) operates.
Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform
by Zacks Equity Research
Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and stable liquidity.
Teleflex (TFX) Rides on Urolift Prospects Amid Cost Pressures
by Zacks Equity Research
With respect to Teleflex's (TFX) market development objectives for UroLift, the company witnesses growth for UroLift in the hospital setting.
Teleflex (TFX) Picked for Vizient Innovative Technology Exchange
by Zacks Equity Research
Teleflex (TFX) gets selected to exhibit Arrow VPS Rhythm DLX Device and Arrow PICCs preloaded with the NaviCurve Stylet at the Vizient Innovative Technology Exchange.
Alcon (ALC) Gains From Innovation & International Expansion
by Zacks Equity Research
Alcon's (ALC) Surgical business continues to gain from diverse portfolio and incremental innovation.
Teleflex (TFX) New Survey Highlights BPH Impact Life Quality
by Zacks Equity Research
Teleflex's (TFX) survey results highlight how crucial it is for men to consult a urologist if they have strange or troublesome urine symptoms.
Charles River (CRL) Announces Partnership With Related Sciences
by Zacks Equity Research
Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.
Quest Diagnostics (DGX) to Aid Health Equity With New Pact
by Zacks Equity Research
Quest Diagnostics (DGX) and Americares will provide 10 clinics with no-cost diagnostic services for a year to help patients manage chronic disease.
Here's Why You Should Retain SmileDirectClub (SDC) Stock for Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub (SDC) on the latest technology enhancements and upbeat guidance.